Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection (RIPI)

Evaluation of Post Infectious Inflammatory Reaction (PIIR) in a Retrospective Study Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection

As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions. Some of them are delayed and provide Post infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and PIIR have probably a suboptimal management. In this context the investigators aim to explore PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS invasive infections.

Study Overview

• Status: Unknown
• Conditions: Streptococcus Pyogenes Infection; Streptococcus Pneumonia; Neisseria Meningitides Meningitis

• Study Type: Observational
• Enrollment (Anticipated): 150

Contacts and Locations

• Study Contact: Name: Eric JEZIORSKI; Phone Number: 33 04 67 33 57 98; Email: e-jeziorski@chu-montpellier.fr

Study Locations

• France
  • Montpellier, France, 34295
    • Recruiting
    • Uhmontpellier
    • Contact: Eric Jeziorski, MCU-PH; Phone Number: 33 04 67 33 66 03; Email: e-jeziorski@chu-montpellier.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Pediatric population

Description

Inclusion criteria:

• Less than 18 years of age
• Fever associated with GAS, NM, or SP invasive infection

Exclusion criteria:

• age > 18 years
• Impossibility to obtain the consent of parents / legal representatives.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe the frequency PIIRs	Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	Describe the characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	1 day

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Predictors of PIIRs	Identified the predictors of PIIRs in order to find warning symptoms	1 day

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Study Director: Eric JEZIORSKI, University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2020
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): December 30, 2021

Study Registration Dates

• First Submitted: October 13, 2020
• First Submitted That Met QC Criteria: October 13, 2020
• First Posted (Actual): October 20, 2020

Study Record Updates

• Last Update Posted (Actual): October 28, 2020
• Last Update Submitted That Met QC Criteria: October 26, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: post-infectious inflammatory reactions; Neisseria Meningitis
• Additional Relevant MeSH Terms: Pathologic Processes; Central Nervous System Diseases; Nervous System Diseases; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Central Nervous System Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Streptococcal Infections; Gram-Positive Bacterial Infections; Pneumonia, Bacterial; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Meningococcal Infections; Neisseriaceae Infections; Pneumococcal Infections; Inflammation; Infections; Communicable Diseases; Pneumonia; Pneumonia, Pneumococcal; Meningitis, Meningococcal; Meningitis
• Other Study ID Numbers: RECHMPL20_0550

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: NC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No